Clinical Trial

The Gut Microbiome and Immunotherapy Response in Solid Cancers

Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is characterize the gastrointestinal microbiomes of patient with solid cancer undergoing standard of care treatment with programmed cell death protein 1 (PD-1) /programmed cell death ligand (PD-L1) blockade.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-09-15; most recent amendment 2025-12-12.
Trial Details
NCT Number NCT06050733
Lead Sponsor The University of Texas Medical Branch, Galveston
Conditions Cancer
Enrollment 16 participants
Start Date 2023-06-30
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-19